Sugi Predict

Sugi Predict / Compounds / SCHEMBL3099307

SCHEMBL3099307

SCHEMBL3099307

CC(Oc1ccc([N+](=O)[O-])cc1)c1c(F)ccc(Cl)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSPB1 P04792 2/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ MET P08581 7/20 0.40
▸ KDR P35968 4/20 0.40
▸ SRC P12931 2/20 0.40
▸ FGFR2 P21802 2/20 0.40
▸ AXL P30530 2/20 0.40
▸ FLT3 P36888 2/20 0.40
▸ MST1R Q04912 2/20 0.40
▸ KIT P10721 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ HTR2A P28223 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.37
▸ INPPL1 O15357 2/20 0.36
▸ AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104563 0.91 HSPB1 (0.42) HSPB1MEN1KMT2ALMNAMET
SCHEMBL3109670 0.90 MET (0.50) METKDRSRCFGFR2AXL
SCHEMBL3099647 0.89 LMNA (0.44) HSPB1MEN1KMT2ALMNAMET
SCHEMBL3102498 0.88 HSPB1 (0.40) HSPB1MEN1KMT2ALMNAMET
SCHEMBL3093667 0.84 KMT2A (0.41) HSPB1MEN1KMT2ALMNAMET
SCHEMBL3094219 0.83 HSPB1 (0.45) HSPB1MEN1KMT2ALMNANPC1
SCHEMBL3104424 0.80 HSPB1 (0.42) HSPB1MEN1KMT2ALMNANPC1
SCHEMBL3104697 0.79 MET (0.47) METKDRSRCFGFR2AXL
SCHEMBL3099651 0.77 HSD17B10 (0.42) HSPB1MEN1KMT2ALMNAMET
SCHEMBL3093192 0.73 MET (0.53) METKDRSRCFGFR2AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 — — US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 — — US disclosed
CN-101827827-A Derivatives of 6-aryl/heteroalkoxybenzothiazoles and benzimidazoles, method for preparing same, use thereof as medicaments, pharmaceutical compositions and novel use thereof, in particular as CMET inhibitors SANOFI AVENTIS 2010-09-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 HSPB1 3222/4885MEN1 842/4885KMT2A 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.